Now, scientists from the Perelman School of Medicine at the University of Pennsylvania reveal that the release of AMPs is partially controlled by bitter taste receptors in the upper airway on a cell previously identified in animals and only recently in humans known as solitary chemosensory cells (SCCs). What’s more, the action of the bitter receptors is blocked when sweet taste receptors are stimulated by sugars such as glucose. This study, published online ahead of print in the Journal of Clinical Investigation, suggests that sweet taste receptors expressed on SCCs in the upper airway sense bacterial overgrowth and, in turn, control the release of AMPs.
In previous work, Penn researchers found that bitter taste receptors in the human airway play a role in detecting bacterial communication molecules and launching a defensive response to combat bacteria. The new study complements the prior findings by revealing another defensive response mediated by taste receptors.
“Chronic rhinosinusitis is a common upper respiratory infectious and inflammatory disorder that impacts nearly 35 million Americans, with related health care costs exceeding $6 billion annually,” said senior study author Noam Cohen, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at Penn and staff surgeon at the Philadelphia VAMC. “Despite how widespread this condition is, we still struggle to understand exactly how to best fight it. We’re just now starting to discover how taste receptors in the upper respiratory tract are used to regulate the immune system against these infections, so defining the underlying mechanisms at play is critical to understanding these illnesses and developing new treatments.”
Cohen said that the current study is the first to elucidate a functional role for sweet receptors in the human airway. “This could have critically important clinical consequences, as we found that patients with chronic sinusitis have elevated glucose concentrations in their nasal secretions compared with control individuals, which likely impairs their respiratory immunity. Because prior studies have shown that hyperglycemic patients also exhibit elevated nasal glucose levels, it is likely that the sweet taste receptor function we demonstrate here may also contribute to the predisposition of diabetic patients to airway infections.”
Sweet Vs. Bitter
To study the role of sweet taste receptors, Cohen and lead study author Robert J. Lee, PhD, a post doctoral researcher in his lab, partnered with colleagues from the Children’s Hospital of Philadelphia and the Monell Chemical Senses Center to analyze cultures and tissue samples from the upper respiratory tract of patients who were undergoing sinonasal surgery for a variety of conditions.
The research team, using multiple approaches including live-cell imaging techniques, demonstrated that activation of bitter taste receptors (T2Rs) on SCCs engages a signal to surrounding cells, which stimulates release of high concentrations of AMPs capable of killing a variety of pathogens, including antibiotic-resistant bacteria. While previous research in the last year has shown that SCCs exist in humans as well as animals, the current study was the first to reveal a function for SCC’s in the human airway.
The team also found that compounds that activate the sweet taste receptor (T1R2/3) suppressed the release of the AMPs produced by bitter taste receptors, indicating that these receptors have complimentary roles in regulating the innate immune pathway. They hypothesize that this system may control microbial overgrowth in the airway to maintain a colonized state within the upper airway without infection.
“We believe that the complimentary roles of the bitter and sweet taste receptors in these SCCs keeps upper airway colonizing bacteria at optimal levels during periods of relative health,” Cohen says. “But as the bacteria multiply, they consume more glucose, removing the sweet taste receptor ‘brake’ and allowing for release of AMPs by the bitter taste receptors.”
Cohen says that in the future, clinicians may be able to use certain compounds, such as sweet-receptor blockers, to activate the solitary chemosensory cell innate defense pathway, even in the presence of pathologically high glucose concentrations, to help regulate bacterial growth and prevent harmful infections and chronic inflammation.
The research was supported by National Institutes of Health (DC03055), the Flight Attendants Medical Research Institute (082478), and a philanthropic contribution from the RLG Foundation, Inc.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report‘s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania — recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital — the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.